• Vyome signed exclusive licensing agreement with Impetis Biosciences, TATA Enterprise, covering a selective JAK 1/3 inhibitor plus a selective JAK1 inhibitor for development and commercialization.
• Deal expands pipeline beyond lead program VT-1953, positioning company to enter broader immuno-inflammatory indications.
• JAK inhibitors market projected to reach USD 56.78 billion by 2030, up from USD 23.56 billion in 2025.
• Consideration structured to be tied to commercialization, with any future development planned through non-dilutive pathways.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512782680) on May 12, 2026, and is solely responsible for the information contained therein.